Clinical Trials

A clinical trial evaluated the therapeutic application of abametapir for head lice infestation. Sponsored by Dr. Reddy's Laboratories Limited, this Phase 2 study assessed the safety and pharmacokinetic parameters of topically applied gel formulations in pediatric populations. Recruitment for this trial has been successfully completed.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02010333 Completed
Head Lice Infestation
Dr. Reddy''s Laboratories Limited
2013-04 Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Abametapir product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Abametapir acts as a small-molecule inhibitor that directly targets and chelates metal ions essential for metalloproteinase catalytic function. By blocking metalloproteinase activity, the compound disrupts biochemical processes critical for louse survival and egg development, thereby inhibiting ovicidal and pediculicidal viability. This targeted enzymatic inhibition directly underlies its clinical utility in resolving head lice infestation.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.